≡

Multiplex Assay Kit for Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay)

ErbB-1; ErbB1; ER1; ERB-B1; MENA; HER1; Erythroblastic Leukemia Viral(v-Erb-B)oncogene Homolog,Avian; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 85-95 90
EDTA plasma(n=5) 86-98 92
heparin plasma(n=5) 92-102 97

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 97-105% 92-99% 93-101% 79-89%
EDTA plasma(n=5) 81-104% 87-101% 79-101% 91-105%
heparin plasma(n=5) 86-98% 83-101% 79-104% 95-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:EGFR) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Thoracic Cancer Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer Wiley: source
J Cent Nerv Syst Dis.? Increased Epidermal Growth Factor Receptor (EGFR) Associated with Hepatocyte Growth Factor (HGF) and Symptom Severity in Children with Autism … Pubmed:25249767
Mol Cancer Ther GC1118, an anti-EGFR antibody with a distinct binding epitope and superior inhibitory activity against high-affinity EGFR ligands PubMed: 26586721
Cell Death Dis.  LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway Pubmed:26938303
analytica chimica acta Microfluidic immunosensor based on mesoporous silica platform and CMK-3/poly-acrylamide-co-methacrylate of dihydrolipoic acid modified gold electrode for cancer biomarker detection. pubmed:28335979
Talanta EGFR detection in extracellular vesicles of breast cancer patients through immunosensor based on silica-chitosan nanoplatform Doi: 10.1016/j.talanta.2018.10.016
Bioorganic Chemistry Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers Pubmed: 30665034
Journal of enzyme inhibition and medicinal chemistry Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile Pubmed: 30919701
Bioorganic Chemistry Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents
Bioorganic Chemistry Synthesis and anticancer activity of bis-benzo [d][1, 3] dioxol-5-yl thiourea derivatives with molecular docking study Pubmed: 31288134
Oxidative Medicine and Cellular Longevity Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters … Pubmed: 31737175
Neoplasia Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine Pubmed: 33212364
Association between Serum Epidermal Growth Factor Receptor and Cyclooxygenase-2 Levels in Patients with Non-small Cell Carcinoma of Lung
Synthesis, EGFR-TK inhibition and anticancer activity of new quinoxaline derivatives
IMMUNOLOGIC RESEARCH Humoral immune response to epidermal growth factor receptor in lung cancer 33495907
European Journal of Medicinal Chemistry Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure¨Cactivity relationship and biological activity as potential antitumor and anticonvulsant agents 33545637
Journal of Molecular Structure Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors
ACS Appl Mater Interfaces Emitter–Quencher Pair of Single Atomic Co Sites and Monolayer Titanium Carbide MXenes for Luminol Chemiluminescent Reactions 34914377
Bioorganic Chemistry Discovery of new pyrimido [5, 4-c] quinolines as potential antiproliferative agents with multitarget actions: Rapid synthesis, docking, and ADME studies Pubmed:35219045
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPA757Mu01 Recombinant Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
RPA757Mu02 Recombinant Epidermal Growth Factor Receptor (EGFR) Positive Control; Immunogen; SDS-PAGE; WB.
PAA757Mu02 Polyclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
PAA757Mu01 Polyclonal Antibody to Epidermal Growth Factor Receptor (EGFR) WB; IHC; ICC; IP.
SEA757Mu ELISA Kit for Epidermal Growth Factor Receptor (EGFR) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA757Mu Multiplex Assay Kit for Epidermal Growth Factor Receptor (EGFR) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.